Alexion Pharmaceuticals Inc (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2009

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Alexion Pharmaceuticals, Inc.
Ticker: ALXN CIK: 899866

Exhibit 99.1

Contact:

Alexion Pharmaceuticals, Inc.

Irving Adler

Sr. Director, Corporate Communications

203-271-8210

Makovsky & Company

Mark Marmur (Media)

212-508-9670

Rx Communications

Rhonda Chiger (Investors)

917-322-2569

LOGO

Alexion Reports Fourth Quarter and Full Year 2009 Results

CHESHIRE, Conn., Feb 11, 2010 (BUSINESS WIRE) — Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN):

— Soliris® Net Product Sales Increased 49% to $386.8 Million in 2009 —

— Continued Strong Uptake of Soliris By New Patients in U.S. and Europe in Q4 —

— Soliris Development Programs Advance in aHUS and Transplant —

Fourth Quarter 2009 Financial Highlights:

•

Q4 2009 revenues increased 43% to $110.6 million, compared to $77.4 million in Q4 2008.

•

Q4 2009 GAAP net income was $237.1 million, or $2.59 per share, which includes $215.5 million from a non-recurring tax benefit. Excluding this one-time tax benefit, net income was $21.6 million, or $0.24 per share.

•

Q4 2009 non-GAAP net income increased to $28.5 million, compared to non-GAAP net income of $21.1 million in Q4 2008. Q4 non-GAAP earnings per share increased 35% to $0.31 per share, compared to $0.23 per share, in Q4 2008.

2009 Financial Highlights:

•

2009 revenues increased 49% to $386.8 million, compared to $259.1 million in 2008.

•

2009 GAAP net income was $295.2 million, or $3.26 per share, which includes $215.5 million from a non-recurring tax benefit. Excluding this one-time tax benefit, 2009 net income was $79.7 million, or $0.88 per share.

•

2009 non-GAAP net income increased to $108.4 million, compared to non-GAAP net income of $56.8 million in 2008. 2009 non-GAAP earnings per share increased 84% to $1.18 per share, compared to $0.64 per share, in 2008.

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 11, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Alexion Pharmaceuticals, Inc..

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/899866/000119312510037748/d10k.htm